Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease

<table>Hepatic volume since the initiation of mTOR inhibition therapy. Two-year followup by MRI. Month 0 = switch CsA to sirolimus. Month 24 = stop sirolimus because of absence of reduction growth of the hepatic volume and edema attributed to sirolimus.</table>

Case Reports in Transplantation

fig1

Figure 1

Figure 1: Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease 

Figure 1 | Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease 